Ultra-stable pharmaceutical compounds 

A recent study published in the prestigious journal Science Translational Medicine describes a new anti-hemorrhagic molecule engineered for high stability. This capability is highly significant in the field of coagulation, as it could lead to a longer therapeutic window, allowing for a reduction in the number of injections and, consequently, improving the quality of life for treated patients.

The study, which involves Dr. Alessio Branchini and Prof. Mirko Pinotti from LTTA, in collaboration with an international research team with expertise in immunology, biochemistry, and coagulation disorders, can be found at the following link:
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics.

Specifically, the drug combines the characteristics of coagulation factor VII, which helps prevent/stop hemorrhages, with those of albumin, a protein that naturally circulates in our blood and has high stability. The union of these two features gives the engineered factor (the drug) the ability to be effective for a longer period within the bloodstream.